Jasplakinolide's Inhibition of the Growth of Prostate Carcinoma Cells In Vitro With Disruption of the Actin Cytoskeleton
The DOI matches its Crossref record.
Abstract
BACKGROUND: Jasplakinolide, a cyclodepsipeptide produced by an Indo-Pacific sponge, Jaspis johnstoni, has been reported to inhibit the growth of breast cancer cells. PURPOSE: The effects of jasplakinolide on the proliferation of three human immortalized prostate carcinoma cell lines (PC-3, LNCaP, and TSU-Pr1) were studied. The growth-inhibitory effect of jasplakinolide on the PC-3 cell line was studied in detail to elucidate its mechanism of action. METHODS: Cell counts were used to study growth inhibition. A protein-based microplate assay was used to assess the time of exposure needed to cause persistent growth inhibition and to study the effects of jasplakinolide analogues. Metabolic changes were assessed by following the incorporation of radiolabeled precursors. The effects of jasplakinolide on the cytoskeleton were studied by fluorescent microscopy, using rhodamine phalloidin (RP) and antibodies to cytoskeletal components. Changes in RP binding were quantified by extracting bound fluorescent material from fixed cells and measuring the amount of fluorescence in a spectrofluorometer. RESULTS: The growth of PC-3, LNCaP, and TSU-Pr1 cells was potently inhibited by exposure to jasplakinolide for 48 hours; doses of jasplakinolide that led to 50% growth inhibition were 65 nM for PC-3 cells, 41 nM for LNCaP cells, and 170 nM for TSU-Pr1 cells. In PC-3 cells, exposure to 160 nM for 48 hours led to total growth inhibition, which persisted for several days even after drug removal. Several jasplakinolide analogues also inhibited the growth of PC-3 cells, although analogues in which the rigidity of the macrolide ring was altered were ineffective. No early changes in the synthesis of DNA, RNA, or protein or in intracellular adenosine triphosphate levels were seen in the PC-3 cells after exposure to jasplakinolide. Growth inhibition by jasplakinolide was accompanied by striking morphologic changes. Exposure for several doublings led to multinucleated cells. Further investigation of these changes in the PC-3 cells revealed a dramatic and early disruption of the actin cytoskeleton and a statistically significant decrease in RP binding. The doses of jasplakinolide, the time of exposure, and the pattern of growth inhibition by structural analogues corresponded with the changes seen in actin distribution. CONCLUSIONS: Jasplakinolide represents a novel marine natural product with potent in vitro antiproliferative activity against human prostate carcinoma cell lines, and it appears to target the actin cytoskeleton. IMPLICATIONS: Jasplakinolide is a potential candidate for further preclinical development and a lead structure for a novel class of therapeutic agents that can disrupt the actin cytoskeleton in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rotsch, C., & Radmacher, M. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76614-8 · Cited by 971
Ayscough, K. R., Stryker, J., Pokala, N., Sanders, M., Crews, P., & Drubin, D. G. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.399 · Cited by 735
Self-citationDiverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660
Microtubules and actin filaments: dynamic targets for cancer chemotherapy
Jordan, M. A., & Wilson, L. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80095-1 · Cited by 614
Effects of Jasplakinolide on the Kinetics of Actin Polymerization
Bubb, M. R., Spector, I., Beyer, B. B., & Fosen, K. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.7.5163 · Cited by 525
Metadata
- Authors
- Senderowicz, A. M. J., Kaur, G., Sainz, E., Laing, C., Inman, W. D., Rodriguez, J., Crews, P., Malspeis, L., Grever, M. R., Sausville, E. A., & Duncan, K. L. K.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-01-04
- Volume
- 87
- Issue
- 1
- Pages
- 46-51
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2132823860
- Cited by
- 150
- References
- 0
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Jasplakinolide's Inhibition of the Growth of Prostate Carcinoma Cells In Vitro With Disruption of the Actin Cytoskeleton. https://app.cochat.ai/papers/10.1093/jnci/87.1.46
- The paper
- Senderowicz, A. M. J., Kaur, G., Sainz, E., Laing, C., Inman, W. D., Rodriguez, J., Crews, P., Malspeis, L., Grever, M. R., Sausville, E. A., & Duncan, K. L. K. (1995). Jasplakinolide's Inhibition of the Growth of Prostate Carcinoma Cells In Vitro With Disruption of the Actin Cytoskeleton. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/87.1.46
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.